Associated Papers
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.
Park J et al.
Targeted Oncology, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR.
Das R et al.
Cancers, 2022
Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis.
Talvitie EM et al.
Neoplasia (new York, N.y.), 2022
Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing.
Kim SY et al.
Jto Clinical and Research Reports, 2022
Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma.
Yin XQ et al.
Frontiers in Oncology, 2022
Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
Shi M et al.
Cancer Genetics, 2021
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.
Qvick A et al.
Molecular Medicine (cambridge, Mass.), 2021
MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.
Socinski MA et al.
Jco Precision Oncology, 2021
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA et al.
Lung Cancer (amsterdam, Netherlands), 2020
Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.
Li J et al.
Frontiers in Oncology, 2020
MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
Lung J et al.
Plos One, 2019
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
Ma PC
Cancer Discovery, 2015
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.
Dhanasekaran SM et al.
Nature Communications, 2014
Comprehensive molecular profiling of lung adenocarcinoma.
Unknown Author
Nature, 2014